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Abstract
The identification of cell surface accessible biomarkers enabling diagnosis, disease monitoring, and treatment of renal
cell carcinoma (RCC) is as challenging as the biology and progression of RCC is unpredictable. A hallmark of most RCC
is the loss-of-function of the von Hippel–Lindau (pVHL) protein by mutation of its gene (VHL). Using the cell surface
capturing (CSC) technology, we screened and identified cell surface N-glycoproteins in pVHL-negative and positive
786-O cells. One hundred six cell surface N-glycoproteins were identified. Stable isotope labeling with amino acids
in cell culture–based quantification of the CSC screen revealed 23 N-glycoproteins whose abundance seemed to
change in a pVHL-dependent manner. Targeted validation experiments using transcriptional profiling of primary RCC
samples revealed that nine glycoproteins, including CD10 and AXL, could be directly linked to pVHL-mediated transcrip-
tional regulation. Subsequent human tumor tissue analysis of these cell surface candidate markers showed a correla-
tion between epithelial AXL expression and aggressive tumor phenotype, indicating that pVHL-dependent regulation of
glycoproteins may influence the biologic behavior of RCC. Functional characterization of the metalloprotease CD10 in
cell invasion assays demonstrated a diminished penetrating behavior of pVHL-negative 786-O cells on treatment with
the CD10-specific inhibitor thiorphan. Our proteomic surfaceome screening approach in combination with transcrip-
tional profiling and functional validation suggests pVHL-dependent cell surface glycoproteins as potential diagnostic
markers for therapeutic targeting and RCC patient monitoring.
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Introduction
The prognosis of advanced renal cell carcinoma (RCC) is poor. Most
RCC cases are insusceptible to chemotherapies or radiotherapies,
which seems to be partly caused by a hypoxia-mediated resistance to
radiotherapy and alkylating agents [1–4]. Since 2006, novel anti-
angiogenic targeted therapies have been available for patients with
metastatic RCC. These therapies rely on a targeted blockade of angio-
genic signaling caused by an aberrant overexpression of proangiogenic
cell surface proteins, for example, vascular endothelial growth fac-
tor and platelet-derived growth factor as well as their corresponding
receptors [5–8]. Despite these novel drugs, identification of addi-
tional cellular treatment targets, screening markers for early stages,
recurrent tumors after nephrectomy, and predictive markers for treat-
ment response is of utmost importance to further improve prognosis of
RCC patients.
The discovery of cell surface glycoprotein biomarkers for RCC
would be clinically useful because these glycoproteins are exposed to
the cellular microenvironment and are, therefore, easily accessible by
affinity-based probes such as drugs and antibodies for disease moni-
toring. Furthermore, cell surface glycoproteins can be shed into the
bloodstream and could provide potential targets for recently developed
remote-sensing serum-screening strategies [9]. However, the identifica-
tion of the cellular surfaceome is challenging owing to its lower abun-
dance compared with intracellular subproteomes, its hydrophobicity
due to transmembrane domains, and the high degree of posttransla-
tional modifications on these proteins. One solution to overcome this
abundance problem is to focus on the cotranslational modification of
cell surface proteins with glycostructures. The recently developed mass
spectrometry (MS)–based cell surface capturing (CSC) technology is
through the glycosylation of cell surface proteins for specific enrichment
of this subproteome and subsequent identification [10]. Glycoproteins
are also of particular clinical interest given that approximately 80% of
all current protein drug targets are glycoproteins [11].
Strategies for the identification of RCC glycoprotein biomarkers can
be combined with available knowledge about cancer-causing muta-
tions. The von Hippel–Lindau (VHL) gene is the most commonly in-
activated gene in the most frequent subtype clear cell RCC (ccRCC).
More than 70% of ccRCCs are characterized by somatic mutations or
hypermethylation of VHL [12–16], whereas in the rare papillary and
chromophobe RCC subtypes, VHL is hardly affected. VHL encodes
two proteins of 30 and 19 kDa, the latter being a result of an alter-
native, in-frame translation initiation codon [17]. Both proteins seem
to differ in part in their subcellular localization, which may imply
potential functional differences [18,19]. The most described function
of pVHL is its role as a substrate recognition component of an E3
ubiquitin protein ligase complex known to target the α-subunits of
the hypoxia-inducible factor (HIF) for ubiquitin-mediated proteolysis
in a prolyl-4-hydroxylation–dependent manner under normoxic con-
ditions [20–23]. HIF is a sequence-specific heterodimeric transcription
factor composed of an α subunit (HIF-1α, HIF-2α, or HIF-3α) and
an invariable β subunit. It promotes adaption and survival under low
oxygen by up-regulation of genes that are involved in neovasculariza-
tion, pH regulation, glucose uptake and glycolysis, apoptosis, and cell
cycle [24]. In ccRCC, the HIF transcriptional program is uncoupled
from changes in oxygen availability and co-opted by the cancer cell
to promote tumor growth. Interestingly, vascular endothelial growth
factor and platelet-derived growth factor, the two major angiogenic
factors successfully targeted by the current above-mentioned therapies,
are HIF target genes.
Here we used the CSC technology to screen and identify N-
glycosylated cell surface proteins in pVHL-negative and -positive cell
lines. The pVHL-dependent glycoproteins detected within the initial
screen were subsequently verified and validated in vitro and in situ
at the transcript and at the protein level by using a combination of
low-density arrays (LDAs) and tissue microarrays (TMAs), respec-
tively. Our pVHL-guided proteomic surfaceome screening approach
in combination with transcriptomic validation and functional char-
acterization revealed pVHL-regulated glycoproteins as candidates for
the clinical use in patients with RCC.
Experimental Procedures
Cell Culture and Metabolic Labeling
The ccRCC-derived cell line 786-O, the human embryonic kidney
cell line HEK-293, and the human fibrosarcoma cell line HT-1080
were supplied by American Type Culture Collection (Manassas, VA).
Stable transfectants of 786-O reexpressing pVHL30 were generated
as mentioned before [19]. RCC4 cells and their corresponding trans-
fectants reexpressing wild-type pVHL30 were created as previously
described [19,25]. Human renal proximal tubular epithelial cell line
HK-2 was provided by R. Wüthrich (Clinic for Nephrology, De-
partment of Internal Medicine, University Hospital Zurich, Zurich,
Switzerland). RCC4, 786-O, HEK-293, and HK-2 cells were cultured
as reported previously [26]. Hypoxic experiments were performed
for 16 hours at 1% oxygen using a hypoxic workstation (Invivo2 400;
RuskinnTechnology, Leeds, UnitedKingdom).Dimethyloxalyl glycine
(DMOG) (Cayman Chemical, Ann Arbor, MI) treatment was per-
formed for 24 hours at 1 mM. Stable isotope labeling with amino
acids in cell culture (SILAC) was used for the in vivo incorporation of
isotopically labeled amino acids into all cellular proteins. For SILAC
labeling, 786-O and their stable transfectants reexpressing pVHL30
were grown in L-lysine and L-arginine–deficient Dulbecco modified
Eagle medium (Sigma) containing 10% vol/vol dialyzed fetal calf serum
(FCS), 2 mM glutamine, and either normal or heavy lysine/arginine.
Cells were grown for five to six generations. Then, 5 × 107 786-O
and 786-OpVHL30 were used for CSC.
CSC-Based Proteomic Surfaceome Screen
Cells were labeled in 10 ml of labeling buffer containing 5 mM bio-
cytin hydrazide for 60 minutes. On labeling, the cells were harvested
by scraping. Oxidation of cell surface glycoproteins subsequent cell
surface labeling, cell lysis, membrane preparation, and final process-
ing, and isolation of N-glycopeptides was performed as described in
Wollscheid et al. [10].
Mass Spectrometry
Peptide samples were analyzed on a hybrid LTQ-FT-ICR instru-
ment (Thermo Electron, Bremen, Germany) interfaced with a nano-
electrospray ion source. Before the LTQ-FT-ICR analysis, peptides
were separated on a RP-HPLC column (75 μm × 15 cm) packed in-
house with C18 resin (Magic C18 AQ 3 μm; Michrom BioResources,
Auburn, CA) using a linear gradient from 96% solvent A (0.15% for-
mic acid) and 4% solvent B (98% acetonitrile, 2%water, 0.15% formic
acid) to 25% solvent B for 60 minutes at a flow rate of 300 nl/min per-
formed by a Tempo Nano 1D+ HPLC system (Applied Biosystems/
MDS Sciex, Foster City, CA).
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Each MS1 scan was followed by CID scans of the five most abun-
dant precursor ions with dynamic exclusion for 30 seconds. Only
MS1 signals exceeding 150 counts were allowed to trigger MS2 scans
with wideband activation disabled. Total cycle time was approxi-
mately 1 to 1.5 seconds. For MS1, 3 × 106 ions were accumulated
in the ICR cell for a maximum time of 500 milliseconds and scanned
at a resolution of 100,000 full width at half maximum (at 400 m/z).
MS2 spectra were acquired in the linear trap using the normal scan
mode, a target setting of 104 ions and accumulation time of 100 milli-
seconds. In the LTQ-FT analysis, singly charged ions and ions with
unassigned charge state were excluded from triggering MS2 events.
The normalized collision energy was set to 32%, and one microscan
was acquired for each spectrum.
Data Analysis
The raw data acquired by the LTQ-FT instrument (software,
Xcalibur 2.0; Thermo Scientific, Waltham, MA) was converted to
mzXML using ReAdW (3.5.1) applying default parameters. MS/MS
scans were searched against the human International Protein Index
(IPI, version 3.15, 58099 protein entries) database using SEQUEST
version 27 with the following parameters. For LTQ-FT data, precursor
mass tolerance was set to 0.1 Da, a minimum of one tryptic termini
was allowed, and variable modifications were allowed on asparagines
(0.9840), on lysines (8.014199), and on arginines (10.008269), with
a maximum of four modifications per peptide. No static modifica-
tions were defined. Data were further processed by the Trans-Proteomic
Pipeline TPP v2.9 including PeptideProphet and ProteinProphet to
estimate the false discovery rate. A protein probability cutoff of 0.8 was
used, which corresponds to a false discovery rate of approximately 1%.
Quantification
For obtaining quantitative ratios between the differentially SILAC-
labeled samples, we applied automated statistical analysis on protein
(ASAP) ratio v3.0 [27]. The algorithm was run with a fixed scan range
for the light and the heavy ions and with no background subtraction
for the peak integration. ASAP ratio is an integrated part of the TPP
and it normalizes the ratio distribution and computes a protein ratio.
The results were curated manually.
RNA Isolation and LDA Applications
RNA from frozen tissue was isolated using the RNAeasy Mini Kit
(Qiagen, Hilden, Germany). The quality and quantity of the isolated
RNA were analyzed by means of nanodrop and Agilent Bioanalyzer
2100. Reverse transcription of isolated RNA was performed by the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems)
according to the manufacturer’s instructions. Pilot experiments using
RNA derived from tumor cell lines and tissue were performed with
selected TaqMan gene expression assays to verify the reverse transcrip-
tion step linearity and to determine the amount of cDNA, which can
be loaded in polymerase chain reaction (PCR) without inhibition. Ap-
plied Biosystems TaqMan LDAs were configured using the online soft-
ware tool TaqMan Custom Array (https://products.appliedbiosystems.
com). Only assays whose probes span an exon junction were chosen
to avoid detection of genomic DNA. Preparation and loading of the
sample-specific PCR mix into the fill reservoirs of the TaqMan Micro-
fluid Cards were accomplished according to the manufacturer’s in-
structions. Relative levels of gene expression were determined from
the fluorescence data generated during PCR using the Applied Biosys-
tems 7900HT Fast Real-Time PCR System followed by computational
analysis by means of SDS and RQ manager software with HPRT1 and
18S rRNA as internal control.
Quantitative Reverse Transcription–PCR
Total RNA from pools of clones of 786-O and 786-OpVHL30
cells, lentivirally infected with shHIF-2α (target constructs 1 and 4)
as well as uninfected control cells, was prepared using the RNAeasy
Mini Kit (Qiagen) according to the manufacturer’s protocol. Reverse
transcription was performed by High-Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). cDNA reverse transcribed from
50 ng of total RNA was used for quantitative reverse transcription
(RT)–PCRs containing 10 μl of TaqMan 2× PCRMasterMix (Applied
Biosystems) and 1 μl of TaqMan Gene Assay (Applied Biosystems) for
CD10 (Hs00153519_m1) or 200 nM primers and 100 nM of the
universal probe library probe 55 (Roche, Mannheim, Germany) for
HIF-2α in a volume of 20 μl. Detection was carried out with a Fast
Real-Time PCR System (7900HT; Applied Biosystems). Data analysis
was performed using the SDS and RQ manager software (Applied
Biosystems). Peptidyl-prolyl cis-trans isomerase A (PPIA) served as an
internal control (Hs99999904_m1).
Tissue Specimen and TMA Construction
We used TMAs comprising 264 ccRCC collected from the Univer-
sity Hospital of Zurich (Zurich, Switzerland) to validate the in vitro
data. All tissue samples were histologic reviewed by one pathologist
(H.M.) and selected on the basis of hematoxylin and eosin–stained
tissue sections [28]. A more comprehensive TMA study was performed
to confirm the HIF dependence of CD10 in ccRCC. We used three
TMAs comprising 831 ccRCC collected at the University Hospital of
Zurich (Zurich, Switzerland), the Kantonsspital St. Gallen (St. Gallen,
Switzerland), and the University Hospital of Basel (Basel, Switzerland).
The composition of the TMAs and clinicopathologic data were pre-
viously described [29]. This study was approved by the local ethics
commission (reference number StV 38-2005).
Immunohistochemistry
TMA sections (2.5 μm) were transferred to glass slides followed by
immunohistochemical analysis according to Ventana automat protocols
(Ventana Medical System, Tucson, AZ). Antibodies were applied for de-
tection of AXL (1:200, AF154; R&D Systems, Planegg-Martinsried,
Germany), CAIX M75 (1:200; kindly provided by J. Zavada, Insti-
tute of Molecular Genetics, Prague, Czech Republic), CD10 (1:30,
NCL-CD10-270;Novocastra Laboratories,Newcastle,UnitedKingdom),
CD13 (1:200, NCL-CD13-304; Novocastra Laboratories Ltd),
CD31, CD34, CD99 (1:25, NCL-CD99; Novocastra Laboratories
Ltd), CCND1 (prediluted, Ventana, P2D11F11 [29]), E-CADH (1:10,
ECH-6; Cell Marque, Rocklin, CA), and SLC2A1 (GLUT-1) (1:1000,
AB1341; Chemicon, Temecula, CA). Analysis was performed with a
Leitz Aristoplan microscope (Leica Microsystems, Wetzlar, Germany).
Pictures of ccRCC specimens were obtained with a digital camera
(KY-070; JVC, Friedberg, Germany). The intensity of the staining for
AXL, CAIX, CD10, CD13, E-CADH, and GLUT-1 was classified as
follows: 0 no, +1 weak, or +2 strong membranous staining. Endothelial
AXL was analyzed to measure the microvessel density of the tumors
as follows: 1 = low (0-10), 2 = median (>10-50 cells), and 3 = high
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(>50 cells). ImmunostainedTMAs were scanned using theNanoZoomer
Digital Slide Scanner (Hamamatsu Photonics K.K., Shizuoka, Japan).
Immunoblot Analysis
Cell and tissue lysates were prepared using RIPA buffer (Sigma,
Steinheim, Germany) containing complete protease inhibitor cocktail
(Roche). Homogenization was performed with a Tissue lyser (Qiagen)
for 4 minutes at 20 Hz. Lysates were centrifuged for 10 minutes
(2500g, 4°C). Protein concentration of the supernatant was deter-
mined by the BCA Assay (Pierce, Rockford, IL) with bovine serum
albumin (BSA) as a standard. The following primary antibodies were
used for the functional characterization of CD10: mouse monoclonal
anti–CA9 M75 (kindly provided by J. Zavada, Institute of Molecular
Genetics; 1:1000), mouse monoclonal anti-CD10 (NCL-CD10-
270; Novocastra Laboratories; 1:100), rabbit polyclonal anti–Glut-1
(AB1341; Chemicon; 1:4000), rabbit polyclonal HIF-2α (NB100-
122; Novus Biologicals, Littleton, CO; 1:1000), mouse monoclonal
anti–β-actin (Chemicon; 1:10,000), and rabbit polyclonal α-pVHLCT
[19] (1:500). After washing with Tris-buffered saline Tween 20, the
membranes were incubated at room temperature with HRP-conjugated
secondary antibody rabbit anti-mouse (Abcam, Cambridge, United
Kingdom; 1:3000) or goat anti-rabbit (MAB1501; Chemicon; 1:3000).
The protein-antibody complexes were detected by ECL (Amersham,
Piscataway, NJ). Biotinylation of proteins was determined by incubating
membranes with streptavidin-HRP (1:5,000). The protein-antibody/
biotin-streptavidin complexes were detected by ECL (Amersham).
ELISA
CD10 concentration in human serum samples of 21 RCC and
6 healthy controls was measured by ELISA (R&D Systems). This
study was approved by the local ethics commission (EK-1017). The
patients’ sera were collected according to the standardized protocol
of the Department of Urology, University Hospital Zurich. Capture
antibody was coated overnight at 4°C in 50 mM Tris-HCl, pH 9.4.
Plates were subsequently blocked using 1% BSA in phosphate-buffered
saline. Samples were diluted 1:5 in diluent buffer, comprising of
1:3 LowCross Buffer (Candor Bioscience, Eggenwatt, Weissensberg),
0.1% goat serum, and 1%BSA in phosphate-buffered saline for 2 hours
at room temperature. The biotinylated detection antibody was di-
luted in diluent buffer and incubated for 2 hours at room temperature
followed by 20 minutes of incubation with streptavidin-HRP and
substrate detection. The serum diluent was shown in separate experi-
ments to efficiently inhibit false-positive and false-negative signals.
Interassay and intra-assay variations were less than 3% and less than
20%, respectively.
Short Hairpin RNA Constructs and Lentiviral Infections
Expression vectors encoding short hairpin RNA (shRNA) sequences
targeting human HIF-2α were purchased from Sigma (shHIF-2α#1,
clone ID NM_001430.x-517s1c1; and shHIF-2α#4, clone ID
NM_001430.x-1694s1c1, respectively). Viral particles were produced
using the ViraPower lentiviral expression system according to the
manufacturer’s instructions (Invitrogen). Briefly, 786-O cells were
infected with lentiviral particles of either shHIF-2α#1 or shHIF-
2α#4 constructs, and pools of clones were derived by puromycin
selection (4 μg/ml). Pools of clones were analyzed for effective HIF-
2α knockdown by quantitative RT-PCR and anti–HIF-2α immuno-
blot analysis.
Reporter Gene Assay
Four different CD10 promoter fragments were obtained by PCR
amplification of human genomic DNA. The oligonucleotide primers
used in this study are summarized in Table W9. PCR products were
sequenced using the AbiPrism 3100 Genetic analyzer (Applied Bio-
systems). The reporter constructs were generated by insertion of indi-
vidual CD10 KpnI-NheI fragments from the human CD10 promoter
into the KpnI-NheI sites of a promoterless pGL4.10 firefly luciferase
reporter gene plasmid (Promega, Madison, WI). Site-directed muta-
tion of HREI in the CD10 promoter was performed on pGL4.10
containing the whole CD10 promoter using the QuickChange II
Site-Directed Mutagenesis Kit (Stratagene, Cedar Creek, TX). For
transcriptional transactivation experiments, HEK-293 and HK-2 cells
were transfected with 1 μg of reporter plasmids along with 100 ng of
pGL4.74 renilla luciferase reporter plasmid (Promega) in 24-well
plates using FuGene 6 reagent (Roche). pGl3P2P(607 bp) vectors
are 5′-truncated versions of the previously published pGl3b(1454/
3172)P2P plasmids containing the wild-type or mutated hypoxia re-
sponse element (HRE) of the human PHD2 promoter [30]. These
vectors served as positive or negative controls for HIFα activity. The
empty pGL4.10 vector served as MOCK control. Luciferase activity
was measured after cell lysis using the dual-luciferase reporter assay sys-
tem (Promega). Luciferase activities were determined by dividing the
relative luciferase units from hypoxic/DMOG–treated and normoxic/
untreated cells. Renilla luciferase control reporters were used for nor-
malization of transfection efficiency.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed according
the protocol (version 10.0) of mammalian ChiP-on-chip (Agilent
Technologies). Briefly, 5 × 107 to 1 × 108 cells grown in normoxia
or hypoxia were fixed in 1% formaldehyde, washed, harvested, and
lysed. The cell lysates were sonicated to fragment cellular DNA into
fragments of 100 to 600 bp in size and incubated with an anti–HIF-
1α (mouse monoclonal, NB100-105; Novus Biologicals) antibody/
magnetic bead (Dynabeads Potein G; Invitrogen) mixture over-
night at 4°C. After washing to deplete unbound DNA, elution of
bounded DNA/antibody complexes from the beads was performed
in elution buffer at 65°C. Beads were separated from the eluent by
centrifugation (16,000g, 1 minute). Cross-linking of DNA and anti-
body was reversed by incubating the supernatant at 65°C over-
night. Finally, cellular protein and RNA were digested by means of
proteinase K and RNase A. DNA was extracted by means of phenol-
chloroform-isoamyl alcohol in Phase Lock Gel tubes (Eppendorf,
NY). DNA concentrations were measured using a nanodrop. SYBR
Green Real-time PCR was performed with 10 ng of isolated DNA in
a 20-μl reaction using a 7900HT PCR cycler (Applied Biosystems)
to quantify the differential binding of HIF-1α to the analyzed HREs
of CD10. The primers used for the ChIP experiments are listed in
Table W9.
Cell Invasion Assay
Cell invasion was assessed using the QCM 24-well fluoromet-
ric cell invasion assay (Millipore, Zug, Switzerland) according to
the manufacturer’s protocol. Cells were starved in serum-free me-
dium for 24 hours. Afterward, 0.5 × 106 cells/ml were seeded into
extracellular matrix–coated inserts and cultured for 72 hours. FCS
was used as a chemoattractant in the bottom chamber. The CD10
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inhibitor thiorphan (Merck, Darmstadt, Germany) was added to
the bottom chamber using the following final concentrations: 1 and
10 μM, respectively.
Statistical and Computational Analyses
Contingency table analysis, Pearson χ2 tests, Kaplan-Meier curves,
and log-rank tests for evaluating correlations between AXL, CD10,
CD13, GLUT-1, and E-cadherin expression and clinical parameters
were calculated using StatView (SAS, Institute, Cary, NC). One-
tailed unpaired t test with Welsch correction to compare CD10 serum
levels in tumor patients with healthy controls was performed using
GraphPad Prism 4 (GraphPad Software, San Diego, CA). Automatic
classification of the LDA expression data was performed using pocus
[31] and R [32] package for assessing the uncertainty in hierarchical
cluster analysis by resampling. Average linkage clustering was per-
formed with correlation as a distance measure using 1000 bootstrap
replications. The random forest algorithm, implemented as R pack-
age, was used for unsupervised classification. It was set to assess the
importance of predictors.
Results
Identification of pVHL-Dependent Cell Surface
N-glycoproteins in ccRCC
The CSC technology was used as an initial screen to identify poten-
tially pVHL-dependent cell surface N-glycoproteins. In brief, cell
surface–exposed glycans were oxidized and tagged with biocytin
hydrazide. Then, the cells were lysed, proteins were digested, and the
tagged peptides were captured with streptavidin. After thorough wash-
ing, N-glycosylated peptides were released with peptide N-glycosidase F,
cleaned up with C18 tips, and subjected to liquid chromatography tan-
dem mass spectrometry (LC-MS/MS) analysis. In a first step, we com-
bined SILAC- and CSC-based labeling and isolation of N-glycosylated
cell surface N-glycoproteins from ccRCC-derived 786-O cells and stable
transfectants reexpressing the long form of wild-type pVHL (referred
to as 786-OpVHL30). Subsequent shotgun proteomics analysis of
enriched N-glycosylated plasma membrane proteins from 786-O and
786-OpVHL30 cells resulted in the identification of 110 proteins
(peptide prophet score ≥ 0.8) (Tables W1–W4 and Figure W1). The
106 proteins, which contained a peptide with at least one consensus
N-glycosylation motif (NXS/T), were subjected to further analysis
(Table W5). In a first in silico functional classification procedure using
the Panther (www.pantherdb.org) and IPA (Ingenuity Systems) classifi-
cation tools, we uncovered significant enrichments of proteins whose
functions have been associated with cell adhesion and cell communi-
cation (Figure 1A). A second analysis focused on the involvement of
the proteins in specific well-described canonical pathways. The iden-
tified proteins are mostly involved in signaling cascades mediated by
integrins, cadherins, and Wnt (data not shown).
Quantification of the pVHL-Dependent Cell
Surface N-glycoproteins
SILAC-based labeling of the screened glycoproteins in 786-O and
786-OpVHL30 allowed for the initial relative quantification of 63 cell
surface proteins (Table W5). Twenty-three proteins (20.5%) met the
criteria of differential expression between pVHL-negative and pVHL30-
positive 786-O (ASAP ratio 0.33 > x > 3). Differential expression
of the HIF target GLUT-1 served as control for the activity of the
HIF pathway and demonstrated the reliability of the measurements
Figure 1. In silico characterization of the identified cell surface proteins. (A) Most prominent molecular pathways at which the iden-
tified cell surface proteins participate. The functional classification of all identified proteins (n = 106) has been performed by using
the PANTHER and KEGG databases. (B) Relative protein expression profiling in ccRCC-derived cells using metabolic labeling of proteins
by SILAC and LC-MS/MS–based peptide identification. pVHL expressing or pVHL-negative 786-O cells were grown in medium containing
heavy- or light-labeled L-Arg/L-Lys isotopes, respectively. Ratios of the peak intensity were computationally calculated by the ASAP ratio
algorithm for every peptide. Shown in the figure is the reconstructed MS1 signal of a pair of light/heavy GLUT-1 peptides detected in
pVHL-positive and -negative cells in the ASAP ratio view. The ratios of the same peptide in different charge states are averaged and
weighted by the corresponding spectrum intensity to obtain the peptide light-heavy ratio and its error. Up-regulation of GLUT-1 in pVHL
(light-labeled) 786-O cells compared with their pVHL-reexpressing transfectants (heavy-labeled) functioned as internal control for the activity
of the HIF pathway. (C) Immunohistochemical validation of the expression of GLUT-1 and EGFR on formalin-fixed and paraffin-embedded
786-O cells. pVHL− indicates 786-O cells lacking the pVHL protein. pVHL+ indicates 786-O cells reexpressing pVHL. The top row repre-
sents cells stained for GLUT-1. The bottom row represents cells stained for EGFR. Figure 3C was modified from Boysen et al. (Pathologe,
2009;30 Suppl 2:188–192). With permission from Springer Science and Business Media.
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(Figure 1B). Immunohistochemical validation on formalin-fixed and
paraffin-embedded 786-O and 786-OpVHL30 cells confirmed the
quantitative MS/MS data (Figure 1C).
In silico functional classification of the 23 differentially expressed
proteins using the Panther database suggested these proteins to par-
ticipate in cell proliferation (EGFR signaling), cell cycle regulation
(p53 signaling), and cell motility (integrin and cadherin signaling) (data
not shown).
LDA-Based Validation of RCC-Associated Cell Surface
N-glycoproteins in Cell Lines and Primary Tumors
In a second step we combined discovery-driven proteomic screening
data with transcriptomic profiling of the preliminary 106 candidates
for validation in vitro. The identified cell surface N-glycoproteins were
validated in vitro by using a customized LDA platform. HPRT1
mRNA and 18S rRNA were used for normalization of gene expres-
sion. Real-time RT-PCR–based amplification of cDNA was detected
for 82 candidates (73.2%; Table W7). Of 23 pVHL-dependent pro-
teins, 15 (65%) also showed a pVHL-related transcriptional regulation
(Table W7).
To validate the pVHL-dependent transcriptionally regulated can-
didates from the 786-O cells in human tissue samples, we expanded
our targeted LDA analysis to RNA samples from ccRCC (n = 6),
pRCC (n = 4), and normal kidney tissue samples (n = 5, pooled).
Of the 73 detectable genes, 34 (46.6%) were differentially expressed
in ccRCC compared with normal kidney (Table W8). Of 73 de-
tectable genes, 25 (34.3%) were differentially expressed in ccRCC
compared with pRCC or normal kidney (Table W8). Thus, we
identified significant differences between normal and tumor tissues
suggesting the existence of a tumor subtype-specific signature. Ran-
dom forest [33] and bootstrapping algorithms (pvclust) identified
the genes that most accurately distinguished between both RCC
subtypes (Figure 2A). The genes THBS1, ENPEP, SLC2A1, BST2,
MME (CD10), ABCB1, and SCARB1 were identified, among others,
as important discriminators between both renal carcinoma sub-
types. To select proteins for subsequent focused tissue-based analysis,
we compared the transcriptomic data obtained from cell lines and
tissue samples. This resulted in a final list of nine genes that showed
concerted deregulation in cell lines and tissues (Table 1).
Moreover, to further study the difference between ccRCC and
pRCC, we performed hierarchical clustering using multiscale bootstrap
Figure 2. Supervised hierarchical clustering on genes analyzed by LDA in the two major subtypes of RCC. (A and B) Molecular subtyp-
ing based on gene expression data derived from 10 RCC samples analyzed by LDAs correlated mostly with the histologic features of
the tumors. Histologic subtypes are named as follows: pRCC—papillary RCC and ccRCC—clear cell RCC. Genes that differentiate most
significantly between the histologic subtypes are listed. (C) TMA-based expression analyses of selected candidates from the initial in vitro
and in vivo measurements. Shown are examples of positive and negative tumors for each protein analyzed.
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resampling (pvclust) of the low-density expression data. This analysis
revealed significant tumor subtype–dependent clustering based on
differentially expressed cell surface N-glycoproteins (Figure 2B).
TMA-Based Expression Analysis of Selected Human
RCC-Specific Protein Candidates
We next performed immunohistochemical expression analysis of
three of the nine candidates listed in Table 1 for which specific anti-
bodies were commercially available. We analyzed the expression pat-
terns of AXL, CD10, and GLUT-1 using a TMA that contained
264 ccRCC (Figures 2C and W2). The associations with pathologic
parameters are listed in Table 2.
AXL protein expression was observed in both tumor cells and
endothelial cells. Only 23 (10.6%) of ccRCCs presented a strong
membranous expression in tumor cells. Epithelial AXL expression
correlated strongly with poor differentiation grade (P = .0002) and
sarcomatoid differentiation of tumor cells (P < .0001).
A high density of AXL-positive endothelial cells correlated signifi-
cantly with high nuclear differentiation grade (P < .0001). An inverse
correlation was found between a high density of AXL-positive endothe-
lial cells and sarcomatoid differentiation (P < .0001). A high endothelial
density determined by AXL correlated with a better patient outcome
(P = .0028, log-rank test).
CD10 positivity was mainly observed in nonnecrotic ccRCC (P =
.0004) and strong GLUT-1 expression was found primarily in tumors
with lower nuclear differentiation grade (P < .0001). There were no
associations with patient survival.
CD10 Is a HIF Regulatory Target in ccRCC
As CD10 was identified as a pVHL-regulated protein, we asked
whether CD10 is also regulated by HIF similar to known HIF targets
CAIX and GLUT-1. We first investigated CD10 expression in VHL-
negative RCC4 and 786-O cell lines as well as in stable transfectants
reexpressing pVHL (RCC4-pVHL30, 786-O-pVHL30). Immunoblot
analysis demonstrated CD10 up-regulation in pVHL-negative cell lines
compared with pVHL reexpressing cells (Figure 3A). HIF-2α protein
levels and the expression of the HIF target gene GLUT-1 correlated
with the expression of CD10 (Figure 3A).
CD10 expression increased under hypoxia (1% oxygen) in HK-2
and RCC4-pVHL30 cells but remained unchanged at high levels
under normoxic and hypoxic conditions in pVHL-negative RCC4
(Figure 3B). The increase of CD10 expression correlated with an in-
crease of HIF-1α and HIF-2α in RCC4pVHL30 cells. In HK-2 cells,
only an increase in HIF-1α was detectable, suggesting that CD10 is
regulated by both HIF-1α and HIF-2α in a cell type–specific manner
(Figure 3B). To confirm up-regulation of CD10 by HIF-2α in ccRCC,
shRNA against HIF-2α was expressed in 786-O using two different
short hairpin constructs (shHIF-2α#1, shHIF-2α#4). The expres-
sion of each construct resulted in a significant reduction of HIF-2α
in 786-O on the RNA and the protein levels, which was accompanied
by a decrease of CD10 mRNA and protein in VHL-negative 786-O
cells (Figure 3, C and D). This strongly suggests that CD10 expression
is regulated by the pVHL-HIF axis.
Next, a computer-assisted search was performed to investigate a
4-kb genomic DNA fragment of the 5′ region flanking the CD10 gene
(EMBL: X79438) for the presence of the HRE RCGTG (R corre-
sponds to A or G) [34–37]. Four potential HREs were identified in
this region. The binding of HIF-1α at the identified HREs was inves-
tigated by using the ChIP approach (Figure 4A). This analysis could
not be performed with HIF-2α because of the lack of antibodies suit-
able for ChIP analysis. The ChIP experiments were performed in
HEK-293 cells cultured in normoxia or hypoxia (1% O2). Hypoxia
induced direct binding of HIF-1α to all four identified HREs in the
5′ region of CD10. The strongest accumulation of HIF-1α under
hypoxic conditions was found at HREII. No binding of HIF-1α was
measured for the negative control gene KCNJ5. Initial experiments
using IgG isotype control antibodies revealed no increased binding
after hypoxic treatment.
We then performed luciferase reporter gene assays to confirm
whether HIF binding at the identified HREs in the 5′ region of CD10
leads to increased luciferase activity. For this purpose, a DNA fragment
containing the 5′ region of CD10 (CD10(−5134/−1005)) was inserted up-
stream of the luciferase cDNA. After transient transfection, HK-2 cells
were treated with or without DMOG. DMOG is a prolyl-4-hydroxylase
inhibitor resulting in normoxic HIFα stabilization and increased HIF
activity. Compared with untreated cells, the luciferase activity of the
CD10(−5134/−1005) reporter gene construct was increased 2.3-fold in
HK-2 (Figure 4B). Specificity of DMOG-induced HIF activity was
shown by using a reporter construct harboring wild-type HREs of the
HIF target gene prolyl-4-hydroxylase domain (PHD) 2 promoter (P2P)
[30]. A 3.9-fold induction of the P2P wild-type reporter (P2PWT) in
HK-2 indicated the activation of HIF after DMOG treatment.
The effect of HIF stabilization on CD10 activation was also inves-
tigated under hypoxic conditions. HK-2 cells transfected with the
CD10(−5134/−1005) reporter construct showed a 1.8-fold increase of
luciferase activity compared with normoxia. These results confirmed
that, in human renal epithelial cells, HIFα stabilization leads to CD10
promoter activation.
Table 1. Final List of Candidate Cell Surface Proteins Specific for ccRCC.
Number Name IPI Entrez Protein 786-O/786-OpVHL30 RNA 786-O/786-OpVHL30 RNA ccRCC/pRCC RNA ccRCC/Normal
1 AXL 00296992 558 0.27 1.75 1.53 2.44
2 BCAM 00002406 4059 1.21 0.23 1.45 0.23
3 CDH2 00290085 1000 0.88 2.04 0.83 4.88
4 CDH6 00024035 1004 1.27 0.37 0.27 3.40
5 F3 00010338 2152 0.22 11.11 0.58 0.10
6 HEG1 00297263 57493 NA 1.82 2.24 0.57
7 MME 00247063 4311 NA 3.7 9.6 0.8
8 SLC22A4 00171334 6583 1.5 2.2 3.0 13.9
9 SLC2A1 00220194 6513 5.5 2.9 8.5 2.2
Genes deregulated on the protein and mRNA level in 786-O cells and differentially expressed in ccRCC compared with pRCC and normal kidney.
NA indicates not analyzed.
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We next performed site-directed mutagenesis to confirm the induc-
ibility of the CD10 promoter by HIF through HREI, which showed
the strongest induction of luciferase activity (Figure W1). HK-2 cells
transfected with a CD10(−5134/−1005) reporter construct containing a
mutated HREI (CD10MUT) were cultured under normoxic or hypoxic
conditions (Figure 4C ). Mutagenesis of HREI resulted in a two-fold
reduction of luciferase activity under hypoxia. There was no induc-
tion of CD10MUT activity under hypoxia compared with normoxia.
Hypoxia-induced HIF activity was verified by a six-fold induction of
the wild-type P2P reporter construct. This result suggests that HREI is
a functional HIF-binding site in the CD10 promoter and that CD10 is
a bona fide HIF target gene.
A comprehensive TMA analysis of CD10 expression in ccRCC
was performed to confirm the regulatory effect of HIF on CD10 in
ccRCC tissue. Three TMAs containing 831 ccRCCs were analyzed
for membrane staining of CD10 and the HIF targets CAIX, GLUT-1,
and CCND1. CD10 expression correlated significantly with CAIX,
GLUT-1 (P < .0001, each), and CCND1 (P = .0005). Because HIF
suppresses E-cadherin gene transcription, E-cadherin expression was
also analyzed. We found an inverse correlation between E-cadherin–
negative and CD10-positive tumors (P < .0001). No correlation was
found between CD10, CAIX, or GLUT-1 expression and survival.
CD10 Inhibition Reduces the Invasive Behavior of
Renal Carcinoma Cells
The effect of CD10 on the invasive behavior of ccRCC cells was
determined using cell invasion assays. For this purpose, 786-O and
786-OpVHL30 were seeded on a reconstituted basement membrane
matrix in the presence or absence of the specific CD10 inhibitor thior-
phan. The highly invasive fibrosarcoma cell line HT-1080 was used as
a positive (with 10% FCS in the lower chamber) or a negative (without
FCS in the lower chamber) control. 786-O cells, which express high
levels of CD10, showed a 1.6-fold enhanced invasive potential com-
pared with 786-OpVHL30 cells (Figure 4D). A 1.9- and 2.3-fold de-
crease of cell invasion was measured after addition of the CD10-specific
inhibitor thiorphan to 786-O and 786-OpVHL30 cells, respectively.
Notably, in the presence of pVHL, 1 μM thiorphan was sufficient to
decrease the invasive potential of the tumor cells. In contrast, in VHL-
negative 786-O, a 10-fold dose (10 μM) of thiorphan was needed to
yield the same effect.
Detection of CD10 in the Serum of RCC Patients
Identification of serum biomarkers for diagnosis, prognosis, or
disease progression monitoring of ccRCC represents an ultimate
goal in renal cancer research. We analyzed thus the potential of
CD10 as ccRCC-associated serum biomarker. CD10 is frequently
expressed in tissue, but its potentially elevated abundance in sera
from patients with ccRCC is unknown [38–40]. Therefore, sera
from ccRCC patients (n = 15), patients with other renal carcinoma
subtypes (n = 6), and normal healthy controls (n = 8) were analyzed
using a commercial CD10-specific ELISA. The analysis showed that
the CD10 serum protein concentration was significantly increased in
a subset of ccRCC patients (494.3 ± 125.8 pg/ml) compared with
healthy individuals (173.7 ± 43.99 pg/ml, P = .01). Patients diagnosed
Figure 3. CD10 expression is increased due to pVHL loss-of-function, HIFα stabilization, and hypoxia. (A) Immunoblot analysis of CD10,
GLUT-1, HIF-1α, HIF-2α, and pVHL expression in 786-O, 786-O-pVHL19, 786-O-pVHL30, RCC4, and RCC4pVHL30. Actin was used as pro-
tein loading control. (B) Immunoblot analysis of CD10, HIF-1α, and HIF-2α expression in RCC4, RCC4-pVHL30, and HK-2 under normoxic
(N, 20% O2) or hypoxic (H, 1% O2) conditions. (C) CD10 expression after silencing of HIF-2α. Western blot analysis of CD10, HIF-2α, and
GLUT-1 expression in 786-O with or with no shRNA against HIF-2α. shRNA expression reduces HIF-2α protein levels followed by a
decrease of GLUT-1 and CD10. Laminin A/C was used as protein loading control. (D) mRNA expression levels of HIF-2α and CD10 in
786-O–positive or –negative for shRNA against HIF-2α.
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with other renal carcinoma subtypes without VHL alterations had
CD10 levels comparable to healthy controls (117.4 ± 25.32 pg/ml;
Figure 5). This result indicates that CD10 may be useful as a po-
tential serum biomarker for the detection of recurrent ccRCC after
nephrectomy or preoperative treatment stratification of RCC patients
based on the tumor subtype.
Discussion
Reliable and specific cell surface protein markers for the early detection
of most cancer types are still lacking. Discovery-driven approaches
thus attempt to identify tumor-specific protein markers, which are
cell surface accessible for drug targeting, or detectable in body fluids,
for example, serum, plasma, or urine, for noninvasive diagnostic analy-
sis. During the last few years, LC-MS/MS–based proteomics became
a powerful technology capable of addressing the needs of the clini-
cal community for biomarker discovery on the protein level. Here,
CSC-based proteomic technology was used for an initial screen to-
ward the identification of potential cell surface glycoprotein targets in
the context of VHL inactivation in ccRCC. The screening data were
validated through transcriptomic, immunohistochemical, as well as
functional assays.
Using a ccRCC-derived model of pVHL-positive and pVHL-
negative cells, we screened for N-glyco-cell surface–exposed proteins.
This initial screen revealed ccRCC-expressed cell surface glycoproteins
including their specific cotranslational N-glycosylation sites. In contrast
to antibody-dependent strategies for cell surface protein identification,
Figure 5. Abundance of CD10 in human RCC samples. CD10 serum
levels in ccRCC patients (n = 15), other RCC subtypes (n = 6), and
healthy controls (n = 6) measured by ELISA.
Figure 4. HIF-1α binds and activates the CD10 promoter, resulting in increased CD10-dependent tumor cell invasion. (A) Binding of HIF-1α
at the CD10 promoter analyzed by ChIP. HREI-IV indicates in silico identified HRE elements in the CD10 promoter; KCNJ5, negative control.
Experiments were performed in HEK-293 cells grown in normoxia or hypoxia. Results are shown as ratios of the amplicons detected under
hypoxia versus normoxia. (B) Luciferase reporter gene assay. Relative luciferase gene expression differences of a reporter construct con-
taining a 4-kb 5′ region flanking CD10 in HK-2 cells treated with hypoxia or DMOG normalized to untreated cells. A cotransfected renilla
luciferase expression vector was used for normalization of transfection efficiency. P2PWT served as positive control for HIF activity. Data
are expressed as mean ± SDs. (C) Relative luciferase activity of a reporter construct containing wild-type or mutated HREI of CD10 after
hypoxic treatment of HK-2 cells. Values are normalized to HK-2 cultured under normoxia. A cotransfected renilla luciferase expression
vector was used for normalization of transfection efficiency. P2PWT served as a positive control for HIF activity. Data are expressed as
mean ± SDs. (D) Inhibition of CD10 by thiorphan reduces the invasive potential of 786-O cells. Invasion of 786-O and 786-OpVHL30 cells
through a biomatrix was quantified fluorometrically in the absence or presence of the indicated concentrations of thiorphan. Data are
expressed as mean ± SDs. RFU indicates relative fluorescence unit.
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we could identify ccRCC glycoproteins through their N-glycosites
using the complementary CSC technology for which no commercial
antibodies are currently available. These cell surface–exposed glyco-
proteins and potential diagnostic markers are currently invisible for
antibody-based phenotyping strategies. The combination of the CSC
technology with relative SILAC-based quantification of the surfaceome
in the context of pVHL expression enabled us to detect potential
changes in the protein expression pattern within the detected pool
of RCC glycoproteins. These relative quantitative changes of glyco-
proteins in the cell surface location render the cells’ capabilities to
communicate with the microenvironment, limiting or enhancing sig-
naling capacities. We were also able to further subdivide the cell
surface proteome into pVHL-dependent and nonassociated pathways.
A clear separation into pVHL-dependent and pVHL-independent
pathways may improve the efficiency and decrease unwanted adverse
effects of future therapeutic strategies. Our initial proteomic screen-
ing results suggested that, besides known pVHL-dependent pathways
(e.g., inflammation, MAPK, cadherin signaling), additional signal-
ing pathways such as the endothelin pathway contribute to ccRCC
carcinogenesis [41].
Our screen of the surfaceome indicated CD10 and AXL as pVHL-
regulated cell surface proteins. The molecular mechanism of the cell
surface metalloproteinase CD10 regulation in ccRCC was so far
unknown. Previous studies have reported variable expression of
CD10 in human sporadic ccRCC [38,39,42]. Here we demonstrate
that the activation of CD10 is directly regulated through HIF, which
occurs as a consequence of loss of pVHL function in ccRCC. In addi-
tion, cell invasion assays implicate CD10 in ccRCC progression po-
tentially linked to increased invasive behavior. Indeed, inhibition of
CD10 by the specific inhibitor thiorphan resulted in a reduced invasive
behavior of tumor cells. Interestingly, pVHL-expressing tumor cells
weremore sensitive to lower amounts of thiorphan than pVHL-negative
tumor cells. The therapeutic efficiency of CD10 inhibitors may thus
depend on the VHL mutation status in ccRCC patients.
Serum assays, enabling early diagnosis of ccRCC patients are cur-
rently lacking. Shedding and accumulation of tumor-specific cell sur-
face proteins, such as CD10, in the body fluids exploited for novel
ELISA-based strategies would allow earlier diagnosis of primary tumors
or metastasis occurring after nephrectomy, resulting in improved prog-
nosis of ccRCC. On the basis of our proteomic results and the hypoth-
esis that proteins such as the cell surface protein CD10 might also be
shed in the serum, we established and tested an ELISA to analyze the
serum protein levels of CD10. This analysis revealed a significantly
higher CD10 serum level in VHL-related ccRCC compared with
normal controls and non–VHL-related RCC subtypes, for example,
papillary RCC (pRCC). Therefore, CD10 may represent a promising
serum marker for ccRCC, which is potentially useful to screen patients
after RCC-related nephrectomy for the development of metastases.
The second interesting candidate, which was discovered in our
relative quantitative experiments, was the receptor tyrosine kinase
AXL. AXL was recently highlighted as a therapeutic target in pancreatic
and lung adenocarcinoma [43,44]. Our immunohistochemical analy-
sis demonstrated that AXL is also expressed in ccRCC cells as well as
in endothelial cells. There was a significant correlation between high
number of AXL-positive endothelial cells and better patient’s outcome.
This finding correlates with the data of previous studies, which showed
an association between high microvessel density in ccRCCmeasured by
the endothelial marker CD34 and better patient’s outcome [45,46].
In contrast, strong epithelial AXL expression is related to parameters
of poor prognosis, for example, high nuclear differentiation grade, pres-
ence of necrosis, and sarcomatoid differentiation. This is consistent
with the recently reported data confirming that epithelial AXL expres-
sion is an indicator of tumor progression in pancreatic cancer, glio-
blastoma, drug-resistant myeloid leukemia, and non–small cell lung
cancer [43,47]. Very recently, AXL mRNA and serum protein levels
were shown to correlate with poor patient prognosis in RCC, but the
exact cellular protein expression pattern was not studied [47]. This
recent identification of AXL the in serum of RCC patients demon-
strates that our SILAC CSC strategy was able to identify, in addition
to CD10, a second ccRCC-specific member of the N-glyco-cell surface
subproteome, which is also shed into bloodstream circulation.
In summary, our proteotranscriptomic screening identified novel
pVHL and HIF-dependent components, which may represent the
basis for novel molecular targeted therapies and diagnostic strategies
in ccRCC. Among a number of interesting candidates, we character-
ized in-depth CD10 as a HIF target gene and show that its inhibition
leads to a less invasive phenotype of ccRCC cells. Furthermore, CD10
and AXL may be promising biomarker candidates for the identification
of ccRCC in serum samples. Further analysis of the pVHL-dependent
surfaceome may thus help to improve current therapeutic applications
toward a more personalized tumor-specific treatment.
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Table W4. List of All SILAC-CSC Experiments Used for the Initial Screen Including the Number of LC-MS/MS Runs.
Experiment No. Description Replicates Mass Spectrometer No. LC-MS/MS Runs Data Set(s)
1 SILAC CSC; 786-O light, 786-3O
heavy labeled
wt/30 replicate 1 hybrid LTQ-FT (Thermo Fisher Scientific) 2 B06-12037_gb5_30-1, B06-12038_gb5_30-2
2 SILAC CSC; 786-O light, 786-O
heavy labeled
control replicate 1 hybrid LTQ-FT (Thermo Fisher Scientific) 2 B06-12039_db5_wt1, B06-12040_gb5_wt2
Listed are the two different experimental settings with a description, an annotation of the replicates, the corresponding number of LC-MS/MS runs, and the mass spectrometer used for the analysis of
the sample.
Figure W1. Relative induction of the luciferase activity of CD10 re-
porter constructs containing the individual HRE. HEK-293 cells
were treated with or without DMOG. Whole-cell lysates were used
for luciferase assay. A cotransfected renilla luciferase expression
vector was used for normalization of transfection efficiency.
P2PWT and P2PMUT served as positive and negative control for
HIF activity. Data are expressed as mean ± SDs.
Table W5. List of Screened Proteins that Were Quantified by Using SILAC CSC.
No. Proteins Name IPI Entrez 786-O/
786-OpVHL30
Ratio
−O/−30 SD
1 ABCB1 IPI00027481 5243 NA NA
2 ADAM10 IPI00013897 102 NA NA
3 ADCY9 IPI00030099 115 0.02 0.01
4 ALCAM IPI00015102 214 1.36 2.08
5 ANO6 IPI00151710 196527 NA NA
6 ANPEP IPI00221224 290 0.64 0.35
7 ASAM IPI00024929 79827 0.57 0.43
8 ATP1B1 IPI00179529 481 NA NA
9 ATP1B3 IPI00008167 483 2.03 0.79
10 AXL IPI00296992 558 0.27 0.32
11 BCAM IPI00002406 4059 1.21 0.46
12 BSG IPI00019906 682 1.10 1.60
13 BST2 IPI00026241 684 1.74 1.06
14 C1QTNF3 IPI00166261 114899 NA NA
15 CA12 IPI00012895 771 NA NA
16 CADM1 IPI00003813 23705 1.12 1.90
17 CD109 IPI00152540 135228 2.61 1.33
18 CD276 IPI00019275 80381 1.37 1.56
19 CD40 IPI00018282 958 NA NA
20 CD44 IPI00002541 960 0.23 0.31
21 CD47 IPI00216516 961 NA NA
22 CD63 IPI00215998 967 NA NA
23 CD70 IPI00031713 970 0.42 0.60
24 CD82 IPI00020446 3732 0.70 0.27
25 CD97 IPI00299412 976 2.68 2.18
26 CDCP1 IPI00290039 64866 1.91 0.96
27 CDH13 IPI00024046 1012 0.36 0.52
28 CDH2 IPI00290085 1000 0.88 0.98
29 CDH6 IPI00024035 1004 1.27 0.46
30 CLDND1 IPI00072743 56650 1.93 1.27
31 DPP4 IPI00018953 1803 0.87 0.32
32 DSG2 IPI00028931 1829 0.15 0.05
33 ECE1 IPI00002478 1889 0.93 0.34
34 EGFR IPI00018274 1956 0.21 0.34
35 ELFN2 IPI00289849 114794 0.48 0.16
36 ENPEP IPI00014375 2028 0.18 0.18
37 EPHA2 IPI00021267 1969 0.72 0.35
38 F3 IPI00010338 2152 0.22 0.14
39 FN1 IPI00022418 2335 NA NA
40 GFRA1 IPI00008148 2674 1.42 0.51
41 GGT1 IPI00018901 2678 NA NA
42 GGT2 IPI00002241 728441 NA NA
43 GPC1 IPI00015688 2817 NA NA
44 GPR126 IPI00217481 57211 NA NA
45 HEG IPI00297263 57493 NA NA
46 HLA-B IPI00004657 3106 NA NA
47 HSPG2 IPI00024284 3339 NA NA
48 ICAM1 IPI00008494 3383 1.02 0.98
49 ITFG3 IPI00396658 83986 NA NA
50 ITGA1 IPI00472202 3672 0.21 0.08
51 ITGA2 IPI00013744 3673 NA NA
52 ITGA3 IPI00215995 3675 0.56 0.46
53 ITGA5 IPI00306604 3678 2.78 1.19
54 ITGAV IPI00027505 3685 1.14 1.60
55 KIAA1549 IPI00397393 57670 NA NA
56 KIRREL IPI00470360 55243 NA NA
57 LTBR IPI00006097 4055 0.25 0.09
Table W5. (continued )
No. Proteins Name IPI Entrez 786-O/
786-OpVHL30
Ratio
−O/−30 SD
58 M6PR IPI00025049 4074 NA NA
59 MCAM IPI00016334 4162 NA NA
60 MICA IPI00107380 3106 0.22 0.08
61 MME IPI00247063 4311 NA NA
62 MPZL1 IPI00022558 9019 NA NA
63 MRC2 IPI00005707 9902 NA NA
64 NCAM1 IPI00185362 4684 NA NA
65 NCSTN IPI00021983 23385 NA NA
66 NPTN IPI00011578 27020 0.12 0.05
67 NRP1 IPI00165438 8829 NA NA
68 NRP2 IPI00029693 8828 NA NA
69 NT5E IPI00009456 4907 1.18 0.61
70 OSMR IPI00022674 9180 NA NA
71 PLXNB2 IPI00398435 23654 0.36 0.29
72 PON1 IPI00218732 5444 NA NA
73 PRNP IPI00022284 5621 0.46 0.43
74 PROCR IPI00009276 10544 NA NA
75 PTGFRN IPI00022048 5738 0.38 0.42
76 PTPRF IPI00107831 5792 2.88 3.27
77 PTPRJ IPI00290328 5795 0.70 0.29
78 PTPRK IPI00015756 5796 0.19 0.08
79 PVR IPI00219425 5817 NA NA
80 PVRL1 IPI00003648 5818 0.19 0.04
81 SCARB1 IPI00177968 949 0.38 0.15
82 SEMA4B IPI00419724 10509 NA NA
83 SERPINF1 IPI00006114 5176 0.59 0.23
84 SIRPA IPI00332887 140885 12.15 4.20
85 SLC19A1 IPI00375452 6573 16.08 5.56
86 SLC1A4 IPI00015476 6509 1.15 0.64
87 SLC22A4 IPI00171334 6583 1.52 0.52
88 SLC29A1 IPI00550382 2030 0.19 0.24
89 SLC2A1 IPI00220194 6513 5.54 2.32
90 SLC39A14 IPI00014236 23516 0.12 0.07
91 SLC39A6 IPI00298702 25800 0.08 0.03
92 SLC3A2 IPI00027493 6520 0.36 0.76
93 SLC44A2 IPI00293074 57153 NA NA
94 SLC4A7 IPI00021058 9497 NA NA
95 SLC6A6 IPI00216143 6533 NA NA
96 SLC7A1 IPI00027728 6541 3.76 5.03
97 THBS1 IPI00296099 7057 7.56 3.36
98 TMEM2 IPI00170706 23670 0.27 0.10
99 TMEM30A IPI00019381 55754 NA NA
100 TNC IPI00031008 3371 0.33 0.45
101 TPBG IPI00009111 7162 1.71 2.76
102 TSHB IPI00000851 7252 NA NA
103 URB IPI00260630 151887 NA NA
104 VASN IPI00395488 114990 NA NA
105 VCAM1 IPI00018136 7412 1.14 1.19
106 VCAN IPI00009802 1462 NA NA
Shown is the list of 106 proteins identified with at least one peptide containing the NXS/T consensus
glycosylation motif. Displayed columns are the protein number, gene name, IPI identifier, Entrez
number, ASAP ratios, SD, and number of peptides used for quantitation from experiments 1 and 2
(Table W4). The shown ratios are L/H. A total of 63 proteins could be quantified. Differentially
expressed proteins are marked bold.
Table W6. List of 23 pVHL-Dependent Cell Surface Glycoproteins Detected in ccRCC Cells.
No. Proteins Name IPI Entrez
1 ADCY9 IPI00009456 115
2 AXL IPI00296992 558
3 CD44 IPI00002541 960
4 DSG2 IPI00028931 1829
5 EGFR IPI00018274 1956
6 ENPEP IPI00014375 2028
7 F3 IPI00010338 2152
8 ITGA1 IPI00743104 3672
9 LTBR IPI00006097 4055
10 MICA IPI00107380 3106
11 NPTN IPI00011578 27020
12 PTPRK IPI00470937 5796
13 PVRL1 IPI00003648 5818
14 SIRPA IPI00332887 140885
15 SLC19A1 IPI00375452 6573
16 SLC29A1 IPI00939219 2030
17 SLC2A1 IPI00220194 6513
18 SLC39A14 IPI00014236 23516
19 SLC39A6 IPI00298702 25800
20 SLC7A1 IPI00027728 6541
21 THBS1 IPI00296099 7057
22 TMEM2 IPI00170706 23670
23 TNC IPI00031008 3371
Listed are the protein number, protein name, IPI number, and Entrez number. The 23 proteins
were differently expressed between 786-O and 786-OpVHL30.
Table W7. List of 82 Candidates Analyzed for mRNA Expression by Using Customized LDAs.
Number Gene Name Entrez Gene ID RNA 786-O/
786-OpVHL30
Protein 786-O/
786-OpVHL30
1 F3 2152 11.11 0.22
2 SLC1A4 6509 4.17 1.15
3 MME 4311 3.70 NA
4 ITGA2 3673 3.03 NA
5 SLC2A1 6513 2.94 5.54
6 NT5E 4907 2.56 1.18
7 SLC29A1 2030 2.50 0.19
8 CCDC80 151887 2.27 NA
9 SLC22A4 6583 2.22 1.52
10 SEMA4B 10509 2.13 NA
11 CDH2 1000 2.04 0.88
12 MRC2 9902 2.00 NA
13 SLC39A14 23516 1.89 0.12
14 PRNP 5621 1.85 0.46
15 HEG1 57493 1.82 NA
16 AXL 558 1.75 0.27
17 ANPEP 290 1.72 0.64
18 CDH13 1012 1.72 0.36
19 GPC1 2817 1.67 NA
20 CA12 771 1.64 NA
21 SLC3A2 6520 1.64 0.36
22 ICAM1 3383 1.56 1.02
23 ITGA5 3678 1.54 2.78
24 ALCAM 214 1.52 1.36
25 KIRREL 55243 1.52 NA
Table W7. (continued )
Number Gene Name Entrez Gene ID RNA 786-O/
786-OpVHL30
Protein 786-O/
786-OpVHL30
26 SLC7A1 6541 1.52 3.76
27 TNC 3371 1.45 0.33
28 TPBG 7162 1.45 1.71
29 ABCB1 5243 1.43 NA
30 ITGA1 3672 1.43 0.21
31 NCAM1 4684 1.43 NA
32 THBS1 7057 1.43 7.56
33 ATP1B1 481 1.41 NA
34 ADAM10 102 1.39 NA
35 GFRA1 2674 1.35 1.42
36 PTPRF 5792 1.35 2.88
37 SCARB1 949 1.35 0.38
38 CLDND1 56650 1.33 1.93
39 SLC44A2 57153 1.32 NA
40 SLC6A6 6533 1.32 NA
41 SLC39A6 25800 1.28 0.08
42 SLC4A7 9497 1.28 NA
43 EGFR 1956 1.27 0.21
44 CD109 135228 1.23 2.61
45 ITGA3 3675 1.20 0.56
46 PTPRK 5796 1.20 0.19
47 TMEM30A 55754 1.20 NA
48 TMEM2 23670 1.16 0.27
49 NCSTN 23385 1.15 NA
50 OSMR 9180 1.15 NA
51 CD63 967 1.10 NA
52 BST2 684 1.09 1.74
53 MPZL1 9019 1.09 NA
54 BSG 682 1.08 1.10
55 HLA-B 3106 1.08 NA
56 ITFG3 83986 1.06 NA
57 NPTN 27020 1.04 0.12
58 EPHA2 1969 0.99 0.72
59 PLXNB2 23654 0.99 0.36
60 ECE1 1889 0.96 0.93
61 HSPG2 3339 0.96 NA
62 CD276 80381 0.94 1.37
63 CDCP1 64866 0.94 1.91
64 NRP1 8829 0.90 NA
65 PROCR 10544 0.90 NA
66 ENPEP 2028 0.88 0.18
67 CD47 961 0.86 NA
68 GPR126 57211 0.86 NA
69 CD97 976 0.83 2.68
70 ADCY9 115 0.80 0.02
71 DSG2 1829 0.80 0.15
72 LTBR 4055 0.78 0.25
73 PTPRJ 5795 0.78 0.70
74 CD40 958 0.78 NA
75 CD44 960 0.70 NA
76 M6PR 4074 0.70 NA
77 VCAM1 7412 0.68 1.14
78 CD82 3732 0.67 0.70
79 MCAM 4162 0.63 NA
80 DPP4 1803 0.53 0.87
81 CDH6 1004 0.37 1.27
82 BCAM 4059 0.23 1.21
pVHL-dependent transcription was defined for relative expression differences between 786-O and
786-OpVHL30 if 0.6 ≥ x ≥ 1.75. Deregulated proteins are marked in bold.
Table W8. List of Candidates Analyzed for mRNA Expression in the Two Major Subtypes of RCC (ccRCC vs pRCC).
No. Gene Name ccRCC/Normal pRCC/Normal Ratio ccRCC/pRCC P value RNA Expression
ccRCC vs Normal
Differential Expression Tissue ccRCC
vs Normal, ccRCC vs pRCC
Differential Expression
Tissue and Cell Lines
1 AXL 2.44 1.59 1.53 .0036 1 1
2 BCAM 0.23 0.16 1.45 .0000 1 1
3 CDH2 4.88 5.88 0.83 .0052 1 1
4 CDH6 3.40 12.42 0.27 .0022 1 1
5 F3 0.10 0.16 0.58 .0000 1 1
6 HEG1 0.57 0.26 2.24 .1700 1 1
7 MME 0.77 0.08 9.81 .0700 1 1
8 SLC22A4 13.88 4.56 3.04 .0304 1 1
9 SLC2A1 2.21 0.26 8.55 .0191 1 1
10 BST2 2.13 0.31 6.92 .0284 1 0
11 CD82 0.16 0.10 1.57 .0000 1 0
12 CDCP1 0.26 1.32 0.20 .0031 1 0
13 CDH13 2.47 0.12 20.61 .0312 1 0
14 ENPEP 3.97 0.45 8.93 .0022 1 0
15 GPR126 4.31 6.17 0.70 .0227 1 0
16 HLA-B, MICA 3.55 1.23 2.89 .0363 1 0
17 HSPG2 1.32 0.25 5.34 .2400 1 0
18 ITGA1 1.54 0.27 5.74 .0800 1 0
19 ITGA5 2.24 0.51 4.43 .0500 1 0
20 MCAM 4.15 0.78 5.35 .0139 1 0
21 NCAM1 0.27 0.13 2.08 .0043 1 0
22 PROCR 2.86 0.79 3.63 .0096 1 0
23 SCARB1 35.98 3.45 10.44 .0061 1 0
24 SLC4A7 0.29 0.24 1.21 .0002 1 0
25 SLC6A6 0.30 0.99 0.30 .0000 1 0
26 THBS1 0.55 0.17 3.34 .0022 1 0
27 TNC 0.10 0.28 0.34 .0000 1 0
28 VCAM1 3.90 4.91 0.79 .0034 1 0
29 DPP4 1.94 3.76 0.51 .0206 0 1
30 ABCB1 0.63 1.67 0.38 .0034 0 0
31 ADAM10 0.71 1.34 0.53 .0008 0 0
32 ADCY9 1.12 0.93 1.21 .4100 0 0
33 ALCAM 1.68 1.21 1.39 .0080 0 0
34 ANPEP 0.48 1.13 0.42 .0086 0 0
35 ATP1B1 0.33 0.51 0.65 .0000 0 0
36 BSG 0.86 0.99 0.86 .2200 0 0
37 CA12 0.61 0.41 1.51 .0013 0 0
38 CD109 2.49 2.09 1.19 .0235 0 0
39 CD276 2.31 2.39 0.97 .0289 0 0
40 CD40 2.84 1.04 2.73 .0108 0 0
41 CD44 1.07 1.02 1.05 .7400 0 0
42 CD47 1.44 1.64 0.88 .0700 0 0
43 CD63 1.38 1.43 0.96 .0297 0 0
44 CD97 1.35 1.32 1.02 .2600 0 0
45 CLDND1 1.15 0.68 1.69 .3600 0 0
46 DSG2 1.38 2.02 0.68 .3000 0 0
47 ECE1 0.95 0.55 1.73 .7200 0 0
48 EGFR 2.16 1.15 1.88 .0700 0 0
49 EPHA2 0.67 0.67 1.01 .0496 0 0
50 GFRA1 1.74 1.14 1.53 .4200 0 0
51 GPC1 1.41 1.93 0.73 .1100 0 0
52 ICAM1 1.36 0.69 1.97 .0266 0 0
53 ITFG3 0.78 1.20 0.65 .0010 0 0
54 ITGA3 0.79 2.53 0.31 .0346 0 0
55 KIRREL 1.18 0.72 1.65 .4200 0 0
56 LTBR 1.85 1.88 0.99 .0017 0 0
57 M6PR 0.84 0.90 0.94 .4100 0 0
58 MPZL1 1.85 2.81 0.66 .0078 0 0
59 NCSTN 0.97 0.98 0.99 .4800 0 0
60 NPTN 0.32 0.21 1.53 .0004 0 0
61 NRP1 2.05 0.80 2.56 .0079 0 0
62 OSMR 1.07 0.99 1.08 .6700 0 0
63 PLXNB2 0.65 0.72 0.90 .0003 0 0
64 PTPRF 0.78 0.79 0.99 .0600 0 0
65 PTPRJ 0.46 0.79 0.58 .0001 0 0
66 PTPRK 1.39 2.17 0.64 .1200 0 0
67 SLC39A6 0.68 0.64 1.07 .0306 0 0
68 SLC3A2 0.67 0.59 1.13 .0021 0 0
69 SLC44A2 0.60 0.80 0.75 .0051 0 0
70 SLC7A1 0.67 0.35 1.91 .0489 0 0
71 TMEM2 2.15 1.31 1.65 .0205 0 0
72 TMEM30A 0.78 0.60 1.30 .1000 0 0
73 TPBG 0.36 0.68 0.53 .0004 0 0
A P value is given for the significance of different mRNA expression in the RCC subtypes. Candidates with different expression in both tissues and cell lines are in bold. Differential expression is defined as 0.5 > x > 2.
Table W9. List of Primers Used in This Study.
Primer Name Sequence
Primers used for the generation of CD10 reporter constructs
CD10 (−5134/−1005) f 5′-ATG CGG TAC CAG CCC ACA TTT TCA CTT TGC-3′
CD10 (−5134/−1005) r 5′-ATG CGC TAG CAC AGC AGA ATG GCA AAT TCC-3′
CD10 (−5134/−3744) f 5′-ATG CGG TAC CAG CCC ACA TTT TCA CTT TGC-3′
CD10 (−5134/−3744) r 5′-ATG CGC TAG CTG AGG GTC TGA CTG TGT TGC-3′
CD10 (−3763/−2391) f 5′-ATG CGG TAC CGG GAG ATG TGG GTA GTC CAA-3′
CD10 (−3763/−2391) r 5′-ATG CGC TAG CTG AGG GTC TGA CTG TGT TGC-3′
CD10 (−2557/−1005) f 5′-ATG CGG TAC CCT TTG AGG AGG AAT CGC TGT-3′
CD10 (−2557/−1005) r 5′-ATG CGC TAG CAC AGC AGA ATG GCA AAT TCC-3′
CD10 MUT f 5′-GCC AAC CGA CCT CCT ACA TCA TAA AAT GAC TAA GAA GGT CTC ACC-3′
CD10 MUT r 5′-GGT GAG ACC TTC TTA GTC ATT TTA TGA TGT AGG AGG TCG GTT GGC-3′
Primers used for the ChIP analysis
KCNJ5_FW 5′-ACC TTA AGC TGT TAC TGG GTC TGG C-3′
KCNJ5_RW 5′-GCC AGA CCC AGT ATC AGC TTA AGG T-3′
HREI_FW 5′-TTT TGG CTG GCT TCT TTA CA-3′
HREI_RW 5′-GGG TAA AAT AAG GCT GAG ACC TG-3′
HREII_FW 5′-AAT TAG CTC GGT GTG GTG GT-3′
HREII_RW 5′-CTG GAG TGC AGT GGT GTG AT-3′
HREIII_FW 5′-TGG ATT CAG GGA GGA AAG G-3′
HREIII_RW 5′-AAC AAT ACA CGG GCT CTT CG-3′
HREIV_FW 5′-GTC CGC AGC TAA GGT CCA G-3′
HREIV_RW 5′-CTC TCC CTC CCC TCA CTC TT-3′
Figure W2. Representative pictures of ccRCC immunohistochemically analyzed with antibodies against AXL, CD10, and GLUT-1. The
magnification of the pictures is indicated (10×, 40×). (A) AXL expression in ccRCC. From left to the right: ccRCC with many strong
positive endothelial cells in microvessels (MVs) and weak cytoplasmatic staining of tumor cells. ccRCC with sparse strong positive
endothelial cells and negatively stained tumor cells. Strong cytoplasmatic expression of AXL in tumor cells. Microvessels are indicated
by arrows. (B) CD10 expression in ccRCC. Strong and weak membranous expression of CD10. (C) GLUT-1 expression in ccRCC. Strong
and weak membranous expression of GLUT-1. Erythrocytes are strong positive and serve as internal control for the staining.
